• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Stephens initiated coverage on Catalyst Pharma with a new price target

    11/18/24 8:40:25 AM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CPRX alert in real time by email
    Stephens initiated coverage of Catalyst Pharma with a rating of Overweight and set a new price target of $35.00
    Get the next $CPRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CPRX

    DatePrice TargetRatingAnalyst
    2/4/2025$28.00Outperform
    Robert W. Baird
    11/18/2024$35.00Overweight
    Stephens
    3/14/2024$27.00Buy
    Citigroup
    3/7/2024$23.00Buy
    BofA Securities
    12/21/2023$30.00Outperform
    Oppenheimer
    8/24/2022$10.00 → $15.50Buy → Neutral
    ROTH Capital
    2/8/2022$9.00 → $12.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CPRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer

      CORAL GABLES, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX) today announced the appointment of William (Will) T. Andrews, MD, FACP as Chief Medical Officer. Dr. Andrews will report directly to the Company's President and Chief Executive Officer, Richard J. Daly, and will serve as a member of the Company's executive leadership team. He succeeds Dr. Gary Ingenito, who is retiring after a successful career and will support the transition in a consulting capacity. "We are pleased to welcome Dr. Andrews to Catalyst. In addition to his foundational work in clinical practice in some of the country's most prestigious hospitals, he b

      6/2/25 8:03:00 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update

      Catalyst Enters 2025 With Strong Momentum; Reiterates Confidence in Full-Year Outlook Delivers Record Q1 2025 Total Revenues of $141.4 Million, a 43.6% YoY Increase FIRDAPSE® and AGAMREE® Drive Sustained Organic Growth, Underscoring Execution Strength Reaffirms Full-Year 2025 Total Revenue Guidance Provided Earlier This Year of Between $545 Million and $565 MillionStrengthens Balance Sheet with Cash and Cash Equivalents of $580.7 Million and No Debt as of March 31, 2025 Conference Call and Webcast to be Held on May 8, 2025, at 8:30 AM ET CORAL GABLES, Fla., May 07, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), today reported f

      5/7/25 4:14:54 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025

      CORAL GABLES, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate at the upcoming BofA Securities Health Care Conference 2025 on Wednesday, May 14, 2025, at the Encore Hotel, Las Vegas, Nevada. Presentation Details:Date: Wednesday, May 14, 2025Time: 8:00 am PTWebcast Link The webcast will be ava

      4/30/25 8:03:00 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CPRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Strategy Officer Sundaram Preethi sold $103,649 worth of shares (3,924 units at $26.41), decreasing direct ownership by 9% to 41,081 units (SEC Form 4)

      4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)

      6/12/25 5:00:42 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chairman of Board of Directors Mcenany Patrick J sold $5,217,338 worth of shares (200,000 units at $26.09), decreasing direct ownership by 4% to 4,281,702 units (SEC Form 4)

      4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)

      6/10/25 5:00:43 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Andrews William T. claimed no ownership of stock in the company (SEC Form 3)

      3 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)

      6/6/25 5:00:46 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care